(Q34669637)

English

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Jacqueline E Paramarta

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dominique L Baeten

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

29 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

R160

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

7 July 2018

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis.

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1186%2FAR4675

21 January 2018

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4261980

26 October 2018

Criteria of the classification of spondylarthropathies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25074046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

release_lnsrulje2jcghem3x7n2bfephu

1 reference

https://api.fatcat.wiki/v0/release/lnsrulje2jcghem3x7n2bfephu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34669637&oldid=2196935188"